BioSpace News Archive

[30-March-2020] ENGLEWOOD, Colo. , March 30, 2020 /PRNewswire/ -- Zynex, Inc . (NASDAQ: ZYXI), an innovative medical technology company specializing in the manufacture and sale of non-invasive medical devices for pain management, stroke rehabilitation, cardiac monitoring and neurological diagnostics, today announced that it has hired Rachelle (Chelle) Van Burkleo as its Vice President of Sale

Tetra Bio-Pharma Inc. , announced today it has filed an amended and restated management’s discussion and analysis for the financial year ended November 30, 2019 (" Restated MD&A "), which is available on SEDAR under the Corporation’s profile. The board of directors of the Corporation, based on the recommendation of the audit committee in consultation with the management of the Corpora

BRILINTA reduced bleeding vs dual therapy in high-risk coronary patients in sub-analyses from Phase IV TWILIGHT trial

Todos expands rights to include Asian countries and to include PCR test kits Corona Diagnostics JV with Emerald Organic responsible for commercialization Dr. Joseph Wee, CEO of Todos Singapore, will lead Asian commercialization effort REHOVOT, Israel and New York, NY, March 30, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Todos Medical Ltd. (OTCQB: TOMDF), a pre-commercial stage in-vitro-diagnostics company focused on the development of blood tests for the early detection of cancer

Technopath Clinical Diagnostics today announced that Northwell Health, New York State’s largest healthcare provider with 23 hospitals and nearly 800 outpatient facilities, is minimizing the risk of spreading COVID-19 by adopting Technopath’s technology platform that safely neutralizes infectious medical waste.

- Total 2020 Charitable Grants to Date Approach $13 Million, Including More than $3 million Devoted to Mental Health -

Medtronic plc (NYSE:MDT) today announced positive results of the Onyx ONE Clear Study that evaluated Resolute Onyx DES in high bleeding risk (HBR) patients with one-month dual antiplatelet therapy (DAPT) in the United States and Japan.

Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) (http://www.otcmarkets.com/stock/GNBT/quote) proudly announced that the company’s subsidiary Olaregen Therapeutics’ wound conforming matrix, Excellagen, has been awarded a Blanket Purchase Agreement (BPA) contract from the National Strategic Acquisition Center (SAC) through the efforts of AvMedical, Olaregen’s Small Disabled Veteran Owned Small Distributor (SDVOSD) partner.

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH) (“Bellerophon” or the “Company”), today announced that it has entered into definitive agreements with several healthcare-focused institutional investors for the purchase and sale of 1,275,000 shares of Bellerophon’s common stock, at a purchase price of $12.00 per share, in a registered direct offering priced at-the-market under Nasdaq rules.

GigaGen Inc., a biotechnology company advancing transformative antibody drugs for infectious diseases, transplant rejection and checkpoint resistant cancers, announced today it has been developing a recombinant polyclonal antibody therapy for the treatment of COVID-19.